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“We have learned to recognise stem cells,  
Not necessarily by what they do in their dependent tissues within an organism,  
But rather by what we can do with them in the laboratory” 
 
Pamela Gehron Robey 2 
 
 
 
To my family 
ABSTRACT 
Do mesenchymal progenitor cells naturally circulate in vivo? Are they fundamentally 
compatible with blood? What mechanism allows them to be in contact with blood? 
How do we make therapeutic cells with blood-compatible properties? Can we optimise 
their survival and therapeutic function upon systemic delivery? How should we best 
isolate and condition therapeutic multipotent mesenchymal stromal (stem) cells (MSCs) 
before infusion, to achieve an optimum and sustainable clinical response in patients? 
This thesis covers many aspects related to these questions. It describes how MSCs 
interact with the instant blood-mediated inflammatory reaction (IBMIR) upon infusion. 
The IBMIR was first documented and characterised after infusion of islet cells. More 
then a decade ago, clinicians observed a cascade of innate immune responses occurring 
after islet cell infusion into the portal vein of diabetic patients in an attempt to reverse 
insulin dependence. This response was characterised by the instant activation of the 
complement and coagulation systems, which was accompanied by platelet adhesion to 
the graft, effector cell infiltration, and rapid graft destruction. The reaction resulted in a 
massive cell loss; 80-90% of the infused cells were destroyed within hours of infusion. 
We wondered if similar events occur after systemic intravenous infusion of MSCs? 
Expression profiling showed that MSCs express typical hemostatic regulators, similar 
to those produced by endothelial cells, but display higher amounts of pro-thrombotic 
tissue / stromal factors on their surface, which trigger the IBMIR after blood exposure. 
This process was dependent on the cell dose, the choice of MSC donor, and particularly 
the cell passage number. Freshly harvested, short-term expanded MSCs triggered only 
weak blood responses in vitro, while cryostorage and freeze-thawing, extended culture, 
and co-culture with activated lymphocytes increased their pro-thrombotic properties. 
Particularly thawed cells, as used in many clinical applications, displayed impaired 
immunomodulatory and blood regulatory properties. Thawed cells showed reduced 
responsiveness to pro-inflammatory and impaired production of anti-inflammatory 
mediators, an increased triggering of the IBMIR, and a particularly strong activation of 
the complement cascade, which resulted in twice as efficient lysis after serum exposure. 
Triggering of IBMIR was augmented when the cells were washed and resuspended in 
human AB plasma before blood exposure, as done during clinical cell graft preparation. 
After infusion to patients, we found increased formation of blood activation markers, 
but no formation of hyperfibrinolysis marker D-dimer or acute phase reactants with the 
currently applied dose of 1-3 x 106 cells per kilogram, demonstrating product safety. 
Triggering of IBMIR could be reduced by culturing MSCs with human platelet lysate, 
or antagonised by cell surface heparin-modification and use of soluble anticoagulants. 
We conclude, that currently applied doses of low-passage clinical grade MSCs are safe 
and elicit only minor systemic effects, but higher cell doses, and particularly higher 
passage cells, should be handled with care. This deleterious reaction can compromise 
the survival, engraftment, and function of these therapeutic cells. 
 
Key words: MSC, multipotent mesenchymal stromal / stem cell, immunomodulation, 
tissue repair, tissue engineering, cell therapy, cryopreservation, systemic cell delivery, 
innate immune response, instant blood-mediated inflammatory reaction (IBMIR), 
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  1 
1 INTRODUCTION 
 
1.1 THE CONCEPT OF STEM AND PROGENITOR CELLS 
In modern biology, the highest degree of “potency” – totipotent – is ascribed to 
the fertilised egg, which forms all other tissues in a complex cascade of differentiation. 
From the inner cell mass of the early embryo, it is possible to isolate the pluripotent 
embryonic stem cells (ESCs) 2, which will differentiate into multipotent progenitors. 
The cells differentiate according to specific germ layers with specialised functionality. 
Yamanaka found that this process is fundamentally reversible (Figure 1) 3, 4, and that 
committed cells also exhibit plasticity to differentiate into tissues of other germ layers, 
e.g. differentiated cells, such as fibroblasts, can be developmentally reprogrammed into 
induced pluripotent stem cells (iPSCs). But how are stem cells naturally maintained? 
Throughout adulthood, stem cells persist at particular sites within the human body, the 
so-called stem cell niches, which will allow stem cells to remain in a quiescent physical 
state of long-term self-renewal. One such site is the bone marrow. Haematopoietic and 
mesenchymal stem cells (HSCs and MSCs) are thought to reside in that reservoir 5. 
While HSCs have become a well-established entity since Weissman’s initial report 6, 
the true stem cell nature and exact phenotype of MSCs is more difficult to pin down 7, 
but efforts are ongoing to better characterise the self-renewing skeletal stem cells 1, 8. 
Initial reports observed that bone marrow stroma contains cells capable of initiating 
clonal growth (colony-forming unit fibroblast, CFU-F) 9, which exhibit multilineage 
differentiation potential in vitro 10-12. The isolated CFU-Fs contain a stem cell fraction 
capable of forming all the tissues within the skeletal segment upon transplantation: 
bone tissue, cartilage, adipocytes, fibroblasts and haematopoiesis-supporting stroma 1. 
MSCs are often isolated via their ability to form CFU-Fs upon plastic adherence, and 
not all these adhering cells will exhibit true stem cell properties. Unsorted CFU-Fs will 
therefore constitute a cell mixture of stromal cells, often commonly referred to as: 
multipotent mesenchymal stromal cells (also abbreviated MSCs), a definition 13, which 
was established by the International Society for Cellular Therapy (ISCT) with the goal 
to establish some minimal criteria for therapeutic cell characterisation. The three 
characteristics for MSCs established in this paper are: fibroblastic morphology upon 
isolation in culture, expression of a set of typical stromal markers – demonstrating the 
absence of contaminating haematopoietic, myeloid, and endothelial cells, and to 
demonstrate multilineage differentiation potential into at least three lineages in vitro. 
The following paragraphs will refer to MSCs isolated according to these criteria. 
 
Figure 1: Differentiation potential, commitment, and developmental reprogramming of cells. 
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1.2 HSCT AND SUPPORTIVE MSC IMMUNOTHERAPY 
 
1.2.1 HSCT and recent experience with supportive MSC therapy 
The pioneering work for haematopoietic stem cell transplantation (HSCT) was 
conducted from the 1950s through the 1970s at the Fred Hutchinson Cancer Research 
Centre in Seattle and led by E. Donnall Thomas, later honoured with the Nobel Price in 
Physiology and Medicine for his studies 14. His work showed that intravenously infused 
bone marrow cells could repopulate the marrow and establish a new blood forming 
system in an immune-deficient recipient. His studies furthermore contributed to the 
understanding of donor-recipient allo-reactivity, the major cause for development of 
Graft-versus-Host Disease (GvHD) 15. An outline on cell transplant incompatibility 
reactions is given in the last section of the introduction. Owing to the donor registries, 
HSCT is the most widely used cell therapy today, with >50.000 procedures conducted 
worldwide per year (2006) 16, and further increases since then 17. To undergo HSCT, 
the stem cell recipient undergoes a procedure called “conditioning” (e.g. reduced 
intensity or myeloablative conditioning), where his body is prepared for accepting the 
new stem cell graft 15. To remove malignancy, chemo- and radiotherapy are employed, 
destroying the majority of malignant cells together with the old hematopoietic system. 
The conditioning is supported by “prophylaxis” against GvHD, infections, and tissue 
toxicity. The most common sources for stem cell transplants are the bone marrow, 
peripheral blood, and umbilical cord blood, with the later two being employed more 
frequently during the recent years. HSCT is used to cure life-threatening malignancy, 
such as haematopoietic disease, cancer, and genetic dysfunction. Until today, HSCT 
remains a risky procedure with many complications, which hamper a broader use 15. 
Our laboratory has contributed in pioneering studies on using therapeutic MSCs 
for HSCT-related complications, such as acute GvHD 18, and severe tissue damage 19, 
as well as to co-transplant MSCs with HSCs to promote engraftment of HSCT grafts 20, 
as reviewed by Tolar et al. 21. The field is progressing quickly, and scientific interest in 
using MSCs for treatment of immune and inflammatory disorders is substantial, 
amounting to around 25% of published literature within the MSC field (in 2012) 22. 
Although clinical translation of MSCs into widespread use is within close reach, major 
challenges remain 22. These are mainly related to issues in MSC production, such as: 
cell product characterisation (functional cell component), cell potency and its loss with 
time in culture, and isolation / culture methods that maximise therapeutic cell efficacy. 
On the patient side, recent attention has focused on the mechanistic basis for rapid cell 
elimination after systemic infusion, anti-donor immune responses to allogeneic MSCs, 
the primary mechanism of action in different clinical situations, the need for disease 
specific assays to assess MSC potency, and the establishment of suitable animal models 
to develop in vivo pharmacokinetic profiling of MSCs. Multi-centre clinical networks 
are essential for increasing subject numbers and scientific output from clinical trials 22, 
to best validate not yet solidly established regenerative / immunomodulatory therapies, 
as opposed to therapies relying on cell engraftment 23. A pressing question remains: 
What is the lowest effective MSC dose to achieve an optimum clinical response with 
minimal expanded MSCs? Response analysis in the Stockholm study group suggests 
that very early passage MSCs have higher therapeutic value 24-26, potentially indicating 
higher potency. Use of short-term expanded MSCs may also reduce production costs. 
  3 
1.2.2 Regenerative and immunomodulatory properties of MSCs  
The regenerative and immunomodulatory properties of MSCs on innate and 
adaptive immune responses have already been reviewed extensively in the past 27-30. 
The cells display a hypo-immunogenic and anti-inflammatory profile, allowing their 
potential use across HLA-barriers 31, 32. Their special properties allow MSCs on the one 
hand to evade host immune recognition for some time, and on the other hand to 
actively modulate or even suppress an ongoing inflammatory response. Naturally, these 
qualities of MSCs occur in a context dependent fashion 27, 28, and are thus affected by a 
large number of parameters, such as the exact specifics of the therapeutic cell product, 
or the predominant inflammatory milieu encountered by the therapeutic cells in vivo, 
which all have to be considered for their optimal clinical use 28, 32. In general, MSCs 
immunomodulatory properties are highly multi-factorial 27, 28, 33, they target many 
different types of effector cells 29, they are enhanced by cell contact 34-36, and they are 
triggered by various environmental cues, a process known as “licensing” (Figure 2) 28. 
The cells have the capacity to secrete a broad array of soluble or surface-bound 
regenerative and anti-inflammatory mediators, which are usually even more effective 
when deposited or enriched in their surrounding tissue environment. The potency and 
outcome of MSCs integrated cellular response (e.g. chemotaxis, differentiation, 
immune-homeostasis or -modulation, and tissue damage regeneration), and in particular 
their pro- or anti-inflammatory phenotype, will be tuned by cues such as the physical 
environment (e.g. oxygen tension, tissue context, mechanical load) and the encounter of 
soluble mediators (e.g. immune cell mediators, such as cytokines and growth factors; 
blood activation products, such as complement anaphylatoxins; and Toll-like receptors, 
e.g. MSC1/2 polarization via TLR3/4, respectively) 28. Taken together, MSCs may act 
like a catalyser – taking up pro-inflammatory mediators from their environment, which 
activates or augments the cells intrinsic production of anti-inflammatory mediators, 
with the potential to moderate local or systemic inflammation 28, 33, 37. 
 
 
Figure 2: Licensing of MSCs by different stimuli tunes their integrated cellular response.                                                 
(Adapted from Doorn J. and Moll G. et al. Tissue Engineering Part B Reviews, 2011) 
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1.2.3 Therapeutic efficacy of MSCs against immune ailments 
The multitude of paracrine mechanisms and broad range of bioactive molecules 
that are employed by MSCs to exert their therapeutic function can be classified into six 
main actions: immunomodulation, anti-apoptosis, anti-scarring, angiogenesis, support 
of growth and differentiation of local stem and progenitor cells, and chemoattraction 27. 
In treatment of the complex systemic immune ailments often occurring after HSCT 
(such as acute GvHD and hemorrhagic cystitis), most of these actions would be highly 
beneficial for the patient, e.g. to restore immune-homeostasis, repair damaged tissues, 
or to reduce bleeding. However, the complex nature of HSCT-related pathologies, the 
great variation between patients and their supportive care, and even variations in 
therapeutic MSC preparation itself, makes every clinical evaluation very challenging. 
The two most basic indicators of treatment success would be a clear clinical response to 
the MSC treatment and an improved patient survival. More sophisticated indicators 
would document a desired bioactivity compared to a well-matched control group.  
At its latest follow-up in our and collaborating centres 18, 39 out of 55 patients 
with steroid-resistant, severe, acute GvHD responded to the MSC treatment (71%), 
with half of the patients achieving a complete and one fifth showing a partial response, 
with a better outcome in children than adults, and no observation of major toxicities. 
The 2-year survival in patients who responded to MSC treatment (52%) was higher 
than previously described for patients with a similar grade of GvHD (10%) 18, and the 
1-year survival was more prominent for early than late passage cells (75% vs. 21%) 25. 
We recently also published a report on alterations in the cellular immune compartment 
of patients treated with third-party MSCs following HSCT compared to placebo 37. This 
study came to the conclusion that MSCs are bioactive, as suggested by a reduction in 
epithelial cell death, and induce a tolerogenic shift in the patients’ immune system. 
MSC treated patients showed increased levels of FOXP3+/IL10+ regulatory T-cells, 
reduced numbers of Th17-cells, and a skewing towards type-2 T-helper cell responses, 
without compromising the protective T-cell immunity. This is of particular importance, 
since T-cells represent the main mediator of graft versus host immune reactions, but are 
also essential for safeguarding the adaptive immunity against recurrent pathogens 37. 
Thus, we can conclude that all three basic indicators of treatment success are given, 
although further improvements in treatment response are desirable. Furthermore, great 
discrepancies exist between the experience at European centres and an industry 
sponsored phase III study in the United States, probably owing to potential variables in 
MSC production and their consequent therapeutic properties (Figure 3) 26. 
In the past years, we conducted systematic follow up studies and retrospective 
patient analysis with the aim to eliminate confounding factors to treatment efficacy, in 
order to stepwise improve the patient response to MSC therapy. One focus was set on 
understanding the fate of MSCs after intravenous delivery and on optimising the 
therapeutic cell product for systemic delivery. Experience with islet cell infusion has 
shown that many therapeutic cells are damaged after systemic delivery by an innate 
immune attack – termed instant blood mediated inflammatory reaction (IBMIR) 38-40, 
which compromises the engraftment and bioactivity of the islets cells in treatment of 
type 1 diabetes (T1D), therefore raising the need for infusion of multiple cell grafts 41. 
It became clear during the last years 39, 40, that overcoming IBMIR related damage to 
the cell graft could prove to be a key factor in maximising the therapeutic efficacy of 
cellular therapies, as outlined in the following sections. 
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1.2.4 Improving the clinical efficacy of therapeutic MSCs 
As outlined earlier, differences in outcome are reported for different centres, 
possibly owing to variables in MSC production and consequent therapeutic properties. 
In order to optimise our product, we first studied the interaction of the most commonly 
(systemically) applied therapeutic MSC product at our facility with human blood. We 
then identified major confounders (Figure 3), which may positively or negatively affect 
the biocompatibility of systemically delivered cells. Eventually, we correlated the cells 
IBMIR response with patient outcome, in order to find out if a higher biocompatibility 
leads to an improved treatment efficacy, which has been the case in developing HSCT, 
but is yet to be proven in therapeutic MSC transplantation. The two first issues arising 
in MSC therapy are the choice of cell donor and tissue origin. Functional characteristics 
of cells from bone marrow and other origins may differ, and need to be tested, e.g. for 
their triggering of IBMIR, if applied systemically. As outlined earlier, MSCs respond to 
environmental cues, potentially also present in donors with an underlying pathology 
(e.g. inflammatory conditions such as T1D, multiple sclerosis, or rheumatoid arthritis), 
which may modulate MSCs phenotype, and consequently affect their therapeutic value. 
It is also well established that the stem cell content in marrow decreases with age 42. 
Non-pathological factors accumulating with donor age may affect MSCs efficacy 43, 
and cells from younger donors may therefore potentially be preferred for clinical use. 
The most evident factor affecting MSCs potency appears to be the time in culture. 
Potency reduces after expansion and particularly after repeated passaging 24-26, 44-51, 
resulting in a gradual loss of progenitor properties and tissue forming capacity 44, 50, 
reduced long-term engraftment 45, lower clinical response and survival benefit 25, 48, and 
increased triggering of IBMIR 24, which compromises cell engraftment and function. 
This may be affected by the choice of culture supplement (the experience above was 
made with cells grown with animal components, containing alpha-Gal-xenoantigen), 
and various other aspects of cell delivery (e.g. the use of fresh or thawed cells) 26. 
 
 
Figure 3: Potential parameters affecting the therapeutic efficacy of MSCs. 
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1.2.5 Basic choices in preparation of therapeutic MSCs 
In summary, it can be said that isolated and culture expanded therapeutic MSCs 
show considerable differences compared to their native primary counterparts in vivo, 
creating unique therapeutic products with each specific isolation protocol used. All 
these cell products may differ to some degree in their therapeutic quality and effect, 
raising the absolute need for an exact clinical product definition and standardisation. 
Below, we have summarised some of the most essential considerations to be taken, e.g. 
when preparing MSCs for systemic delivery (Table 1). Most of the given parameters 
are related to product immunogenicity and to the maintenance of progenitor potential, 
based on the assumption that a transient cell engraftment is desirable / necessary, and 
that regenerative and immunomodulatory properties of MSCs are somehow related to 
their progenitor (stem cell) properties, which may not automatically be the case 23. 
Indeed, it has been shown that the in vitro immunomodulatory properties of MSCs are a 
fundamental property shared by all stromal cells 52. However, cell engraftment and 
mesenchymal tissue formation capacity appear to be most effective with freshly 
isolated bone marrow derived cells, as opposed to cells derived from peripheral tissue 1. 
When studying cell transplant incompatibility reactions, product variations in any of 
these parameters need to be kept in mind, since outcome may differ greatly. 
 
Table 1: Potential parameters affecting the functionality of systemically delivered MSCs. 
Parameter of interest Potential advantage Potential disadvantage 
Progenitor cell source   
   Donor comorbidities Young and healthy donor Old donor, systemic disease 
   Donor recipient matching (Transplant antigen match) (e.g. HLA mismatch) 
     Autologous cell source No rejection, no pathogens Price, time, availability? 
     Third party cell source Readily available, higher dose, 
and repeated administration, 
Easy tracking of long-term cell 
function (X/Y chromosome) 
Immunogenic - when given to 
immunocompentent patient,   
Long term function might be 
compromised (rejection risk) 
   Tissue of origin (High stem cell content?) (Low stem cell content?) 
     Bone marrow High progenitor potential Limited amount / invasive 
     Adipose tissue Abundant / no expansion Possibly lower potency 
     Peripheral blood Easily accessible source No / difficult mobilisation 
     Perinatal tissues High potential / amount Ethical concerns (donor) 
Therapeutic cell preparation   
   Isolation procedure and   
   ex vivo expansion time  
Direct isolation or short-term 
cell expansion (early passage) 
Long-term cell expansion  
(higher passage cells) 
   Maintenance of stemness,   
   and differentiation potential	   Fetal supplements such as FCS that contain stemness factors	   Adult donor derived additives may not promote progenitors	  
   Immunogenicity of culture  
   medium supplements 
Antigen / antibody depleted or 
antigen neutral (autologous) 
Poorly defined, can contain 
antigens (FCS, ABS, PRP) 
   Immunogenicity of washing  
   and cell infusion buffers 
Antigen / antibody depleted or 
human serum albumin (HSA) 
Poorly defined immunogenic 
supplements (FCS or ABP) 
   Cell harvesting, storage,  
   and therapeutic delivery 
Freshly harvested or growing 
cells have optimal bioactivity 
Cryopreserved / thawed cells 
have suboptimal bioactivity 
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1.3 CELL TRANSPLANT INCOMPATIBILITY REACTIONS 
 
1.3.1 Are MSCs naturally in contact with and circulate within blood? 
When studying interactions of culture expanded MSCs with blood, the question 
arises if native MSCs are at times in contact with and circulate within blood 53-55? This 
actually seems to be the case in some exceptional situations, which would prove that 
MSCs have the intrinsic capacity to be in contact with blood, and furthermore, that 
tissue-resident MSCs have the fundamental capacity to extravasate through the vessel 
wall and circulate within blood for some period of time. Our results indicate, that 
isolated and culture expanded MSCs have a compromised haemocompatibility, but that 
it could possibly be preserved (e.g. if production parameters are adjusted for designing 
blood compatible therapeutic cells), or that it could be restored (e.g. by using suitable 
methods to promote the blood compatible phenotype before clinical use of the cells). 
Here, I will try to address some of these essential questions, before addressing the fate 
of conventional therapeutic MSCs after systemic – intravenous – delivery. 
The closest relative to MSCs, which is highly adapted to be permanently in 
contact with blood, are endothelial cells (ECs), lining the interior of blood vessels, 
forming a blood-compatible interface between intra- / extra-vascular compartments 56. 
In contrast, MSCs are tissue cells, which reside in the perivascular compartment 57, 58, 
undergoing oxygen-dependent changes in phenotype according to in situ localisation 59. 
If the EC-interface is damaged, blood will come in contact with tissue components, 
which will then lead to an immediate thrombotic reaction. Interestingly, ECs and their 
progenitors (EPCs) permanently circulate in blood, to be recruited to sites of damage 56. 
Furthermore, circulating ECs and EPCs are phenotypically easily confused with MSCs, 
e.g. when isolated via plastic adherence or if an insufficient panel of surface markers is 
used for characterisation (e.g. both cells express high levels of frequently used CD105). 
But how exactly are ECs adapted to be in contact with blood, and how does their highly 
specialised profile compare to that of culture expanded therapeutic MSCs? To answer 
this question, we conducted EC-profiling on resting and cytokine-activated cultured 
MSCs and compared them to ECs, as summarised below (Figure 4) 24. 
 
Figure 4: Expression intensity of typical factors governing blood-compatibility of ECs and MSCs. 
(Legend: red low-, yellow medium-, and green high-expression; red frame indicates degree of change) 
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ECs are the prototypic blood compatible cells, which can establish a non-
thrombogenic luminal surface through a variety of specialised mechanisms 60. They 
present heparan sulphate on their luminal side, binding factor H and antithrombin, 
strong negative regulators of thrombotic events, a mechanism also employed by MSCs, 
when implanted on a carrier material in vivo, but lost after enzymatic treatment 61. Both, 
ECs and MSCs express typical haemostatic regulators (Figure 4) 24, such as tissue 
factor pathway inhibitor, nitric oxide and prostaglandin producing enzymes, and similar 
amounts of tissue- and urokinase-type plasminogen activator and plasminogen activator 
inhibitor, suggesting fibrinolytic properties, as demonstrated for MSCs in vitro 62, 63. 
Particularly after engagement of activated platelets, MSCs secrete fibrinolytic enzymes 
and exert ECM remodeling activity 62, which may promote damage repair in vivo. 
Culture-expanded MSCs express higher amounts of pro-thrombotic tissue factor and 
platelet agonist collagen 24, as typically found within the stromal compartment 64-68, 
which are both increased after prolonged culture, and further strongly modulated upon 
inflammatory challenge 24. Thus, MSCs are equipped to infiltrate bleeding wounds and 
beneficial for wound closure 19, 69-71, but how do they react when infused systemically? 
Arnold Caplan and co-workers conducted the first study on the feasibility and safety of 
systemic infusion of ex vivo expanded MSCs 72, and found no toxicity. They also tried 
to detect infused MSCs in venous patient blood in a subsequent study 73, and were able 
to detect circulating MSCs in some of the patients shortly after infusion, but not at later 
time points (see “first-pass effect”, discussed in the next section).  
Caplan’s team also studied the presence of native circulating MSCs in healthy 
individuals, or in GCSF-mobilised patients undergoing peripheral blood stem cell 
collection. They were unable to detect any circulating native MSCs in either case 74. 
This goes in hand with recent reports that postnatal circulating stromal precursors are 
absent in the majority of human donors and extremely scarce in the remaining few 75. 
Although the issue of circulating MSCs in healthy adults remains controversial 53-55, it 
appears certain that circulating MSCs are present in blood during the first trimester of 
human development 76, and also found in cord blood 77. In individuals with pathological 
conditions or subjected to strong insults, such as surgery or extensive trauma, cells with 
MSC-phenotype appear to be mobilised into the circulation and can be identified with 
flow cytometry or plastic adhesion assays 78-80. At least in the later case of orthopaedic 
trauma, this can be related to a passive release of fat globules into the circulation 55, and 
may not be related to an coordinated – active egression of MSCs into the circulation. 
Various studies have shown a differential mobilisation of haematopoietic, endothelial, 
and stromal progenitor cells from the bone marrow depending on the predominant 
inflammatory milieu 79, 81-84. I would therefore like to conclude at this stage, that viable 
MSCs are found in blood under particular circumstances, and that MSCs have the 
capacity to be in contact with blood and possibly even to mobilise into the circulation 
(e.g. if activated by appropriate signals, such as inflammatory mediators, blood 
activation products, and complement anaphylatoxins formed upon injury or trauma) 79. 
This does not automatically apply to therapeutic cells, since culture expanded cells may 
change their phenotype and functionality (e.g. size increase leading to embolisation) 47. 
MSCs blood-compatibility may also be affected by various aspects of ex vivo handling 
and preparation for clinical use (e.g. passaging with trypsin, temperature / pH changes, 
cryostorage, immunogenicity derived from culture additives and washing buffers), but 
can possibly be increased if the therapeutic cell processing is adjusted accordingly. 
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1.3.2 Fate of systemically infused MSCs in the microvasculature 
The most commonly used product at our facility is cryobanked, 3rd-party MSCs, 
cultured for 2-4 passages in medium containing FCS 18, 24, mainly used in strongly 
immunocompromised HSCT patients. More recently, also short-term (P1-2) expanded 
autologous MSCs cultured with platelet rich plasma (PRP) have been used. Both 
products may differ in their properties from industrial “universal donor” MSCs, which 
are presumably expanded extensively (>P5), to generate thousands of cell doses from a 
few cell donors for treating a multiplicity of subjects 26. Although great variation exists 
between MSC preparation protocols at different centres, most animal and clinical 
studies using intravenous or intraarterial delivery of culture expanded MSCs, observed 
that MSCs are predominantly embolized in the microvasculature of the lungs or tissue 
capillary beds, respectively, with a rapid demise of the detected signal 54. Two factors 
appear to be responsible for this effect: 1) the increase in MSCs size and other 
phenotypic changes occurring after cell expansion 54, and 2) the triggering of IBMIR, 
possibly augmenting embolisation and cell graft damage in the microvasculature 24. 
Therapeutic MSCs are rapidly cleared from circulation, a phenomenon termed 
“first-pass effect”: the passive cell entrapment in small vessels as a function of cell size 
and deformability, presumably a consequence of MSC enlargement in culture 47, 54, 85-94. 
A first characterisation of MSC size was given by Koc et al. 73, who found a 2-3-times 
larger size for detached MSCs compared to neutrophils on cytospin preparations. An 
often reported size of culture-expanded MSCs is around 10-30 µm 87-94, similar to early 
passage clinical MSCs (size range 10-30 µm, peak at 20-22 µm, Figure 5 and results), 
suggesting that a relevant portion of cells is small enough to pass the microvasculature 
(e.g. see Koc et al. 73). Size increase and other changes are continuously accumulated 
during in vitro culture on standard culture plastic 50, which makes it difficult to predict 
when MSCs acquire an unsuitable phenotype for systemic delivery. The chosen in vitro 
culture specifics (e.g. flasks vs. bioreactor 95, 96, culture surface topology and rigidity 97, 
cell density 98, medium supplementation 99, enzymatic detachment method 100, or use of 
thermo-responsive detachment 101) may greatly affect cell product functionality, thus 
opening many new avenues for optimisation of systemically delivered MSC therapies. 
 Figure 5: Therapeutic MSCs size and embolisation in the microvasculature upon systemic delivery. 
  10 
Early experiments demonstrated that infused MSCs repopulate up to one-third 
of the MSCs in the marrow compartment of recipient animals (>1 month after infusion) 
that underwent marrow ablation to create space for long-term engraftment of MSCs 7. 
Interestingly, none of the infused cells could be detected one week after infusion, thus, 
suggesting engraftment and growth of only few surviving cells after systemic delivery. 
MSCs (their progeny) appeared detectable in lung, liver, thymus, spleen, and marrow 7. 
Similarly, engraftment of MSCs in humans was very limited (1-2% donor cells) 45, 102. 
It was suggested that higher engraftment (without marrow ablation) could be achieved, 
if larger cell numbers are infused, or if cells are infused in regular spaced intervals 7, 32. 
Our clinical experience suggests 103, that the engraftment efficacy of MSCs in HSCT 
patients is altogether fairly limited, with a positive signal for approximately 50% of the 
patients (8/15) and infusions (11/21). MSC donor DNA was detected in several tissues, 
such as lung (25% samples positive), kidney (27%), lymph node (27%), gut (22%), 
bladder (17%), liver (13%), marrow (10%), and spleen (7%), with no apparent homing 
tendency to typical tissue damage sites, and no correlation between MSC engraftment 
and clinical response to MSC therapy. We found no signs of ectopic tissue formation or 
malignant tumors of donor origin 103. Positive detection was furthermore negatively 
correlated with time from infusion to sample collection, with a stronger MSC signal the 
earlier the tissue was sampled 103. No stronger signal was observed when using cells 
from haploidentical donors. Despite the low level of donor cell long-term engraftment, 
infused MSCs exhibited bioactivity and a long-lasting beneficial modulation of several 
immune parameters in HSCT patients 37. 
This may focus our attention on the early events directly after cell infusion. 
Initial studies on the bio distribution of MSCs after infusion suggested that large MSCs 
(diameter 20-24 µm) are instantly lodged in small-diameter capillaries (10-15 µm) of 
typical filtration organs such as lung, liver, kidney, and spleen, which could be partially 
counteracted by the vasodilator sodium nitroprusside (15% reduction in lung signal) 92. 
Schrepfer et al. 88 achieved an even stronger reduction (50% reduction in lung signal), 
when using nitroprusside with smaller murine MSCs (diameter of 15-19 µm). Fischer 
also found better lung passage for smaller cells (MSC vs. MAPC, NSC, and BMMNCs: 
diameter 18, 16, 16, and 7 µm, respectively), with a 30-fold increase for BMMNCs, 
although in no case more than 1-5% of all infused cells passed the microvasculature, 
and blocking of cell surface adhesion receptors did not lead to major improvements 89. 
It thus appears that the large size of stromal cells is not the only factor leading to MSCs 
embolisation upon infusion. Improvements of lung passage could also be achieved with 
anticoagulant heparin 104, and pulmonary toxicity was greatly reduced when adding 
heparin to MSCs 105, avoiding cell aggregation and 95% of clinical symptoms after 
infusion to mice, suggesting an improved lung passage after the use of anticoagulants. 
Quimby et al. 106 compared infusions of fresh and cryopreserved MSCs in a cat-model, 
and found that low doses of allogeneic cryopreserved MSCs were well tolerated, while 
higher doses of cryopreserved, but not fresh MSCs, were associated with a higher 
incidence of adverse events (vomiting during infusion and increased respiratory rate). 
Therefore to summarise, engraftment of MSCs in HSCT patients is low to undetectable, 
and long-term persistence of therapeutic cells was not affected by the degree of HLA-
disparity in these strongly immunocompromised individuals. Kinetics of therapeutic 
cell persistence indicate, that most cells are cleared rapidly after infusion, due to 
embolisation and graft damage in the microvasculature 46. 
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1.3.3 The instant blood mediated inflammatory reaction 
The fast recognition, embolisation, and clearance of the infused MSCs suggests 
the involvement of the IBMIR 39, a sequence of incompatibility reactions of the innate 
immune system, observed after systemic introduction of cell therapies and biomaterials 
into the blood circulation 39. Particularly, the complement, coagulation, and contact 
activation systems are involved in the instant recognition, eliciting consecutive 
activation of platelets and leukocytes, leading to thrombotic and anaphylactic reactions, 
inflammation, and cell graft damage. These events may lead to adverse reactions, 
compromise treatment efficacy, lead to treatment failure (if too many cells are lost) 39, 
and can potentially provide an explanation for the mixed clinical results obtained with 
therapeutic MSCs 91. The following sections will give a brief outline on documentation 
of IBMIR during systemic delivery of islets of Langerhans, hepatocytes, and various 
other types of stromal cell therapies. 
A summary on innate immune responses to therapeutic cells can be found in 
Figure 6 (adapted from Figure 1 in the following review: 39). Upon exposure to blood, 
recognition molecules belonging to different innate cascade systems target altered-self 
and non-self structures on cells. Factor (F) VII, fibrinogen, and tissue factor (TF) are 
“recognition or trigger” molecules of the coagulation system, FXII and high molecular 
weight kininogen (HMWK) of the contact system, and C1q, mannose-binding lectin 
(MBL), and properdin of the complement system. The activation of each cascade 
system triggers amplification reactions. Activation of the coagulation cascade leads to 
the generation of prothrombin and thrombin. Further activation of the contact system 
elicits generation of the potent vasoactive peptide bradykinin from HMWK. In the 
complement cascade, there is a powerful amplification of C3 that initiates generation of 
the anaphylatoxins C3a and C5a, as well as the lytic C5b-9 complex. The activation 
products in turn trigger activation of platelets, polymorphonuclear leukocytes (PMNs), 
and monocytes / macrophages, which result in thrombotic and inflammatory reactions. 
These adverse events, together with complement-mediated cell lysis and coagulation-
mediated sequestration may lead to rejection or serious damage to the cells. 
 
 
 
Figure 6: Incompatibility reactions triggered by innate immune responses to therapeutic cells. 
(Adapted from Nilsson B. and Korsgren O. et al. Trends in Immunology Reviews, 2010) 
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The detrimental effects of IBMIR on cell therapies are already well documented 
in islet cell and hepatocyte transplantation (treatment of T1D and hepatic insufficiency, 
respectively) and should especially be considered in application of non-haematopoietic 
therapeutic cells, which are only poorly protected against the bloods cascade systems 39. 
The clinical infusion of purified islets has long been hampered by the fact that multiple 
cell grafts are necessary to achieve insulin independence 41. Up to four grafts are 
necessary to restore 30% of normal functional capacity 107. Instant islet destruction is 
indicated by a sharp rise in C-peptide levels directly post islet infusion 108-110. Positron 
imaging reveals that up to 50% of the cells are destroyed instantly after infusion 108-110, 
attributed to innate immune responses and haemodynamic shear stress. Hot spots of 
islet activity within the portal branches indicate cell embolisation in clots, comprising 
islet cell dispersion and engraftment in the well-vascularised liver tissue. Innate 
immune reactions may indeed be a key factor in clinical islet graft destruction 39. 
Nilsson and co-workers identified TF, produced by the endocrine cells within the islets 
of Langerhans, as the trigger of the thrombotic reactions 111-113, accompanied by acute 
antibody-mediated complement activation and cell lysis 114, which is amplified by the 
engagement of effector cells, such as platelets and PMNs 115. Similar reactions occur 
after exposure of hepatocytes and MSCs to whole blood 24, 116-118. Stephenne et al. 
demonstrated that cells of mesenchymal ontogeny, such as bone marrow MSCs, 
hepatocytes, adult-liver progenitor cells (ALPCs), skin fibroblasts, and myofibroblasts 
demonstrate pronounced pro-coagulant activity compared to bone marrow HSCs 117. 
While HSCs had a negligible effect, both MSCs and hepatocytes increased clotting by 
50% in stark contrast to ALPCs and fibroblasts, which increased clotting by 80-90%. 
The pro-coagulant activity of different cell types correlated with their expression of TF, 
which was found to be absent in blood compatible ECs expressing high levels of TFPI. 
We also found a weak pro-coagulant activity of MSCs, but not ECs, which correlated 
with their expression of TF, and could be abrogated by blocking the TF-pathway 24. 
Recent findings by Tatsumi and co-workers found a strong TF-expression on adipose 
derived MSCs (ADSCs) 119, which lead to a lethal pulmonary thromboembolism in a 
patient following systemic delivery, and a high mortality rate (85%) was documented 
following intravenous delivery of ADSCs in mice due to pulmonary embolism. This 
did not occur after infusion of uncultured adipose-derived cells, which did not display 
TF or pro-coagulant activity, but TF expression was induced after expansion in culture. 
Adverse effects to MSCs appeared to be more prominent with cryopreserved cells 106. 
Others and we have also reported on complement-activating properties of MSCs 120-122. 
MSCs were shown to activate all three pathways of the complement system 121, despite 
expression of complement regulators: factor H, membrane cofactor protein (CD46), 
complement decay-accelerating factor (CD55), and protectin (CD59). Indeed, some of 
these factors showed a relative lack of expression compared to ECs 120, but increased 
CD59-expression resulted in reduced lysis 122, and improved therapeutic efficacy 123. 
Thus, procoagulant activity of mesenchymal cells is affected by the site of isolation and 
degree of culture expansion: minimal expanded bone marrow MSCs and ECs elicit 
only minor procoagulant activity upon systemic delivery, while mesenchymal cells 
isolated from more distant sites or organs at risk for bleeding (e.g. liver or placenta), 
may display much stronger pro-thrombotic features. Despite basic expression of 
complement regulators by MSCs, a significant portion of therapeutic cells is damaged 
by complement activation upon systemic infusion. 
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1.3.4 Allo- and xenoreactivity in MSC transplantation 
In the previous sections, we have described that MSCs mesenchymal ontogeny, 
the specific isolates anatomical location within the body, and the degree of expansion, 
affect the cells blood compatibility, presumably due to differences or changes within 
the gene expression profile (e.g. as demonstrated for the up-regulation of TF 24, 119), as 
often reported for stromal cells of different origins 124-126 undergoing expansion 50, 127. 
Additionally, two major genetic barriers are embedded in every human, providing the 
genetic basis for transplant incompatibility and graft rejection when being ignored: 1) 
the xenogeneic-barrier between the different species, and 2) the allogeneic-barrier 
between different human individuals. Both aspects are frequently reviewed in the 
context of MSC transplantation, e.g. when discussing cell donor choice for clinical use, 
or the choice of supplements for cell culture and processing 21, 22, 26, 28, 32, 91. Thus, we 
will only briefly summarise some essential background on these important systems, as 
they may potentially affect the functionality of the therapeutic cells (please see table 1). 
The xenogeneic-barrier comprises the phenomenon of inter-species reactivity, 
e.g. between humans and other mammals. A prominent example for xenoreactivity is 
the α-gal epitope, which is not expressed in humans, apes, and Old World monkeys 
(monkeys of Asia and Africa), due to inactivation of the α1,3-galactosyltransferase 128. 
But α-gal is naturally expressed as millions of epitopes per cell in glycolipids and 
glycoproteins in all non-primate mammals, prosimians, and New World monkeys 
(monkeys of South and Central America). Humans express high titers of naturally 
occurring anti-Gal antibody, the most abundant natural human antibody, which 
constitutes ~1% of circulating immunoglobulin in plasma 128. Interestingly, the α-gal 
epitope shares a high degree of structural homology with ABO-antigens, and antibodies 
directed against A- and B-antigens also bind to α-gal 128. The ABO-blood type is 
another immune barrier hampering cell transplantation into immunocompetent hosts. 
Isolated MSCs do not appear to express ABO antigens 129, 130, but clinical cells could be 
contaminated with xeno- and ABO-antigens from culture supplements, and washing 
buffers used for cell infusion, such as fetal calf serum (FCS). Spees et al. found 131 that 
7-30 mg of FCS protein can be incorporated in a typical MSC dose (100 million cells), 
but antigen contamination can be reduced to less than 100 ng (100.000-fold reduction) 
by washing with human serum 131, 132. Alternatives, such as human AB serum (ABS), 
human platelet lysate (HPL), and human platelet rich plasma (PRP) have therefore been 
established in the past decade 133-136. Nonetheless, also human donor substitutes must be 
handled with care, due to inter-individual differences, such as blood and HLA type, and 
prepared accordingly, to minimise adverse reactions 135. The allogeneic-barrier: MSCs 
display a hypo-immunogenic and anti-inflammatory profile, which allows their 
potential use across HLA-barriers 31, 32. Although MSCs fail to elicit immune responses 
in mixed lymphocyte reactions in vitro, and are frequently transplanted across HLA 
barriers without adverse reactions, the extent to which allogeneic MSCs evade immune 
reactions remains controversial 32. Allogeneic MSCs show attenuated immunogenicity, 
but may be rejected over time, which limits their use in tissue replacement due to lack 
of long-term engraftment. However, in absence of instant acute rejection, 3rd-party cells 
may provide sufficient in vivo persistence for eliciting immunomodulatory effects, with 
a safety advantage of being only transiently present. Thus, efficient therapeutic MSCs 
could be understood as homing missiles, avoiding the instant immune response, 
effectively reaching their target to deliver a therapeutic effect, and then vanish. 
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1.3.5 How to prevent or antagonise cell graft failure? 
Since the original description of IBMIR in islet transplantation 14 years ago 38, 
many strategies for cell modification and pharmacological intervention have been 
tested to counteract instant blood response and graft loss occurring after infusion 39, 40. 
Similarly, we have pursued several avenues to improve MSC survival and engraftment, 
in an attempt to increase their therapeutic efficacy, some of which are introduced in the 
thesis results section or outlined below (Table 2). The easiest method to minimise 
IBMIR is to use short-term expanded bone marrow MSCs, which exhibit only minimal 
TF expression and procoagulant activity. Another commonly used practice is to add 
heparin to therapeutic MSCs infusion buffer 105. Soluble heparin may not be sufficient 
to completely counteract strongly procoagulant activity of cells such as islets, ALPCs, 
and ADSCs 38, 39, 117, 119. Stephenne et al. 117 therefore established a new protocol for 
combinatorial use of heparin with bivalirudin, to control ALPCs procoagulant activity 
in patients. Other drugs include thrombin inhibitor melagatran 137, TF-inhibitors 24, 111, 
activated protein C 138, and low molecular weight dextran sulphate (LMWDS) 139. Cells 
have also been subjected to conditioning with L-arginine, cyclosporine A, enalapril, or 
nicotinamide in order to change their inflammatory phenotype, and particularly 
nicotinamide had a favourable effect on reducing TF expression, leading to a reduction 
of IBMIR in vitro 112.  Further, pre-infusion culture recovery of cryopreserved MSCs 
improved both their immunomodulatory 140 and blood regulatory properties in vitro 141. 
The use of high doses of MSCs – freshly harvested from culture – lead to an reduced 
incidence of adverse events in and animal model, when compared to similarly high 
doses of cryopreserved cells 106. Other studies also suggest that blood compatibility and 
lung passage of MSCs can be improved by modification of culture supplements 105, 
washing buffers 142, and enzymatic cell detachment method 100. Furthermore, strategies 
for non-invasive cell surface modification of therapeutic cells with macromolecular 
heparin-conjugate and PEG-lipid derivatives are being envisioned 143-146. 
 
Table 2: Methods to tackle triggering of IBMIR by therapeutic MSCs considering risk of bleeding. 
Bleeding risk Feasible types of intervention to tackle triggering of IBMIR by MSCs 
None 
Short-term expanded bone marrow MSCs exhibit only minimal TF expression and 
display minimal triggering of IBMIR compared to other cell sources 24,	  119 
Adaptions in culture medium / infusion buffer to increase blood compatibility, e.g. 
substitution of FCS / ABP by other supplements (e.g. ABS or PRP / HSA) 99,	  142 
Pre-infusion conditioning with substances that reduce procoagulant activity, e.g. 
nicotinamide reduces TF expression and triggering of IBMIR in vitro 112 
Pre-infusion culture recovery of MSCs improves their immunomodulatory 140 and 
blood regulatory 141 properties and reduces adverse events in animal models 106 
Minimal 
Soluble heparin in infusion buffer reduces cell aggregation, pulmonary toxicity, 
and dampens IBMIR after intravenous delivery of MSCs 24,	  38,	  105 
Non-invasive cell surface modification with macromolecular heparin-conjugate or 
PEG-lipid derivatives reduces triggering of IBMIR by therapeutic cells 143-­‐146	  
Substantial 
Systemic anti-coagulation in patients with drugs such as melagatran, heparin, and 
bivalirudin may only be recommended in individuals without bleeding risk 117,	  137 
 
  15 
2 AIMS OF THE THESIS 
 
The overall aim of this PhD project was to increase our understanding on the fate and 
function of systemically delivered MSCs in vivo in an attempt to increase their 
therapeutic efficacy. A particular focus of this PhD thesis was therefore given to the 
instant innate immune response to therapeutic cells, commonly known as the IBMIR. 
 
Specific aims: 
 
Study I: 
• To study the interaction of culture expanded human MSCs with the human 
complement system and to study the resulting effector cell responses in blood in 
order to optimise the efficacy of this immunomodulatory treatment. 
• To study the complement compatibility of ECs and MSCs, and to elucidate the 
complement-mediated crosstalk between MSCs and blood-borne immune 
effector cells and the resulting immunomodulatory environment. 
 
Study II: 
• To investigate whether MSCs trigger the IBMIR after exposure to blood from 
healthy donors in vitro and after systemic – intravenous – infusion into strongly 
immunocompromised HSCT patients. 
• To compare ECs and MSCs expression of pro- and antithrombotic factors under 
resting and activated conditions and their consecutive triggering of the IBMIR. 
• To study the impact of typical therapeutic MSC production / clinical application 
related parameters on the triggering of IBMIR: 
o Variation between MSC donors / cell batches / cell lines 
o Effect of MSC passage number / culture time 
o Effect of cell dose / safety assessment 
 
Study III: 
• To compare the blood compatibility, immunomodulatory properties, and 
clinical efficacy of freshly harvested compared to freshly thawed cryopreserved 
MSCs in treatment of immune ailments in HSCT patients. 
• And in particular, to study the triggering of IBMIR, the complement activating 
properties, the clinical response and long-term engraftment of freshly harvested 
compared to freshly thawed cryopreserved MSCs. 
 
Study IV: 
• To investigate a possible harmful impact of highly immunogenic ABO blood 
group antigens at all given steps of MSC therapy in HSCT patients, from cell 
isolation and preparation for clinical use, to recipient response and outcome. 
• To study ABO antigen expression in resting and activated clinical grade MSCs, 
ABO antigen adsorption from culture media supplements or washing buffers 
used for cell infusion, and subsequent whole blood and patient response. 
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3 SUBJECTS, MATERIALS, AND METHODS 
3.1 ETHICAL CONSIDERATIONS 
All the MSC recipients and donors gave informed consent and the Research 
Ethics Committee of Karolinska University Hospital approved all studies and 
experimental procedures in accordance with the policy on human care. The studies 
followed the principles for medical research according to the guidelines of the 
Declaration of Helsinki. 
 
3.2 MSC RECIPIENTS AND THERAPEUTIC CELLS 
A total of 200 MSC infusions, given for complications associated with HSCT at 
Karolinska University Hospital, Huddinge, Sweden, and Leiden University Hospital, 
The Netherlands, between 2002 and 2012, were evaluated in the different studies (I-IV: 
with 48 MSC recipients included in Stockholm, and 25 MSC recipients in Leiden). The 
patients received conditioning and routine GvHD prophylaxis according to previously 
published procedures 18. The main indications for treatment were acute GvHD and 
hemorrhagic cystitis. Most of the MSCs were obtained from 3rd party unrelated donors, 
but also MSCs from HLA-identical siblings, and haploidentical donors were used. 
Response was classified as complete response, partial response, stable disease, and 
progressive disease, as defined previously 24,18, and patients were judged to have 
responded if they had a complete or partial response. Tissue samples taken at autopsy 
or colonoscopy from 15 of the patients were analysed for engraftment using PCR for 
MSC donor DNA 3. Quantification of patient blood counts, D-dimer, fibrinogen, 
albumin and creatinine was performed by diagnostic routine methods. 
Human MSCs were obtained from bone marrow aspirates of healthy volunteer 
donors, and isolated and characterised as described previously 18, 147. To isolate MSCs, 
bone marrow aspirates of approximately 50 ml were taken from the iliac crest of 
healthy donors (n=50; median age, 37; range, 1 to 68 years). The expansion and 
characterisation of MSCs was performed according to the guidelines of the MSC 
Consortium of the European Blood and Marrow Transplantation Group (EBMT) and 
approved by the Swedish National Board of Health and Welfare 18, 20. Briefly, bone 
marrow mononuclear cells were separated over a gradient of Redigrad (GE Health 
Care, Sweden), washed and resuspended in DMEM low-glucose medium (DMEM-LG; 
Invitrogen, USA); supplemented with 100 IU/ml penicillin, 0.1 mg/ml streptomycin, 
and 10% FCS (Hyclone, USA), and plated at 1.6 x 105 cells/cm2. When the cultures 
neared confluence (>80%), the cells were detached by treatment with trypsin and 
EDTA (Invitrogen) and replated / passaged at a density of 4.0 x 103 cells/cm2 for up to 
four passages, and given at a median dose of 1.7 x 106 cells/kg (range 0.7 – 4.2 x 106). 
For rapid availability, most of the cells were stored in liquid nitrogen and freshly 
thawed for IV infusion. Flow cytometry analysis indicated that the MSCs were positive 
for CD73, CD90, and CD105 but negative for CD14, CD31, CD34, and CD45. 
Adipogenic and osteogenic differentiation after induction was evaluated as previously 
described 147. The MSC suspensions were culture-negative for bacteria and fungi and 
PCR-negative for different strains of Mycoplasma 18, 20. 
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3.3 IMMUNOLOGICAL AND MOLECULAR STUDIES 
3.3.1 Blood preparations and complement inhibition (Study I to IV) 
Blood and serum preparation: Fresh non-anti-coagulated human blood for the 
preparation of complement active serum, whole blood flow cytometry, and Chandler 
whole blood loop experiments was obtained from healthy volunteers who had given 
informed consent in accordance with the Helsinki Protocol and received no medication 
for at least 10 days. Complement active normal human AB serum (NHS) was processed 
within 1 hour of blood collection and stored at -70°C, to maintain complement activity. 
In all experiments that made use of human serum, the final concentration of NHS, or 
EDTA-inactivated serum (NHS/EDTA) was 50% (v/v). Whole blood flow cytometry 
was performed with lepirudin anti-coagulated blood (Refludan; 0.05 mg/ml, Hoechst, 
Germany). Lepirudin is a specific thrombin inhibitor that maintains complement 
function in blood 148. Chandler whole blood loops were conducted as outlined below. 
Complement inhibition: Blood and serum were treated with cyclic compstatin 
Ac-I[CV(1MeW)QDWGAHRC]T (1628 Da) 149, or inactive linear control peptide Ac-
IAVVQDWGHHRAT (1532 Da), and C5aR antagonist AcF-[OPdChaWR] (896 Da) 
150, or its inactive control peptide Phe-[Orn-Pro-dCha-Ala-D-Arg]. The inhibitors and 
the control peptides were produced in the laboratory of J. D. Lambris, situated at the 
University of Pennsylvania, USA. 
 
3.3.2 Cell culture and preparation of cells for experiments (Study I to IV) 
Cell culture: Isolation and culture of MSCs for all experimental studies was 
conducted as described above for the clinical MSCs. For comparison to conventional 
culture in medium, containing 10% FCS as supplement, MSCs from the same donor 
were also expanded in medium containing 5% human ABS or PRP. Human umbilical 
vein ECs (Promocell, Germany) were grown in EC growth medium, supplemented with 
100 IU/ml penicillin and 0.1 mg/ml streptomycin, and replated at 10,000 cells/cm2. In 
study IV, we included the adenocarcinoma cell line HPAF-II (blood type A Se/Se) as a 
positive control for ABO transcript expression, which was cultured in the same media 
as the MSCs (DMEM-LG, 10% FCS, plus Penicillin / Streptomycin). 
Cell preparation: Cells used for blood/plasma/serum experiments were 
obtained either from frozen cryo-stocks (liquid nitrogen), or from sub-confluent cell 
layers that had been washed with PBS, to remove non-adherent or dead cells, and then 
detached with trypsin and EDTA. Briefly, to freeze MSCs, the cells were reconstituted 
in 4°C ABP containing 10% DMSO and allowed to cool down to -80°C in a rate 
controlled freezing vessel, and then transferred into the liquid nitrogen tank. For 
prospective, donor-matched comparison of fresh or thawed MSCs from the same batch, 
cells were adjusted to 1-2 x 106 cells/ml in PBS/EDTA containing 5% ABP, and split in 
two equal fractions. One fraction was kept at 4°C to simulate waiting time before 
infusion, the other fraction was reconstituted in 4°C cold ABP containing 10% DMSO, 
and allowed to freeze down at -80°C. Before addition to the blood/plasma/serum 
experiments, cryopreserved MSCs were thawed and washed twice with PBS containing 
5% ABP to remove the toxic DMSO. In study IV, MSCs were briefly washed in 10% 
O plasma to remove DMSO, and then reconstituted and counted in fresh PBS 
containing 10% ABP, or alternatively 10% HSA, as outlined in study IV. 
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3.3.3 Interaction of therapeutic cells with serum and blood (Study I to IV) 
Serum exposure of cells: Serum preparation and cell treatment was conducted as 
outlined in detail in study I and III. While in study I, NHS from individuals was used, 
in study III, a pool of 5 NHS donors was used, to obtain an averaged lysing activity, 
and a longer serum incubation time was chosen (60 min at 37°C, instead of 20 min). 
Briefly, the cells were mixed with an equal volume of serum in sterile polystyrene 
FACS tubes (Becton Dickinson, USA), and incubation was carried out at 37°C. 
Complement activity was stopped by adding EDTA to a final concentration 10 mM. As 
controls, non-serum treated cells and cells treated with NHS/EDTA were included 120. 
Supernatants were harvested after pelleting cells by centrifugation at 900g for 5 min, 
and frozen at -70°C, for ELISA analysis. In experiments requiring the presence of Ca2+ 
(detection of MBL, C1q, Ficolins, and Annexin-V), cells were prepared under non-
chelating conditions with binding buffer (10 mM HEPES/NaOH, pH 7.4, with 140 mM 
NaCl and 2.5 mM CaCl2) from BD 151. Pellet fractions to be analysed with Western blot 
and flow cytometry were collected after three washes with PBS/EDTA, or binding 
buffer, or regular culture medium containing Ca2+ and Mg2+ ions. 
Total cell number and cell viability in suspension was assessed with the 
automated electrical impedance-based Cell Counter and Analyser System Model TT 
(CASY-TT; Roche, Germany), or with a classical haemocytometer (trypan method). 
Apoptotic and dead cell analysis was conducted with flow cytometry, according to the 
manufacturers instructions (FITC Annexin-V Apoptosis Detection Kit II, BD) 151. 
Viable cells are FITC Annexin V (AV) and Propidium iodide (PI) negative; cells that 
are in early apoptosis are FITC AV positive and PI negative; and cells that are in late 
apoptosis or dead are both FITC AV and PI positive. 
Complement activation and binding: SDS-PAGE was performed in a Mini-
Protean 3 electrophoresis apparatus according to the supplier (Bio-Rad, USA). The 
cells were prepared as described above. To remove unbound proteins, cell pellets were 
washed three times with 10 mM PBS/EDTA, resuspended with protease inhibitors 
(Sigma-Aldrich, Sweden) and incubated with 0.1 M methylamine (pH 9.0) for 1 hour at 
37°C, to disrupt the covalent linkage of C3 fragments to cells. Proteins were solubilised 
with lysing buffer (1% SDS, 10 mM Tris-HCl pH 7.4, and protease inhibitors) and cell 
debris was pelleted at 13,000g. Equal amounts of protein were separated on a 10% 
SDS-PAGE, electro blotted onto a PVDF membrane (Perkin-Elmer, USA), and probed 
with a 1:8000 dilution of a horseradish peroxidase (HRP)-labelled rabbit anti-human 
C3d-HRP and anti-C3c-HRP antibodies (Dako, Denmark). Blots were developed using 
enhanced chemo-luminescence detection kit (Western Lightning; Perkin-Elmer, USA). 
Purified C3b, iC3b, and C3d (1 µg/lane) were used as positive controls for immune 
detection. Flow cytometry was conducted on extensively washed cell suspensions, 
labelled with respective antibodies, fixed with 1% paraformaldehyde, and analysed on a 
LSR-II Fortessa (BD). Acquisition was performed in a forward / sideward scatter dot 
plot. Excluded debris (%), and signals of 2,000 – 10,000 gated events was quantified, 
with detection of median fluorescence intensity, and analysed with Summit (Dako). 
The cells were labelled with the following mouse-anti-human antibodies (all from BD): 
isotype IgG1-FITC, and IgG2a-PE; negative controls CD45-FITC, and CD14-PE; 
positive controls CD73-PE, CD90-FITC, and CD105-PE (Ancell, USA); and a panel of 
antibodies against different complement regulatory proteins and complement initiators 
(see overview table in manuscript III). 
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Time lapse microscopy imaging: Freshly detached and thawed MSCs (P2-4) 
were seeded at a density of 1 x 106 cells/ml in 24-well flat bottom plates modified with 
an Ultra-Low Attachment surface (Costar; Corning, USA), and exposed to either active 
or inactivated serum as outlined above, and described in detail in manuscript III. 
Imaging was performed at 37°C on a Leica DMI6000 wide field microscope with an 
EM-CCD 16-bit camera (Evolve; Andor Technology PLC, Northern Ireland), with an 
exposure time of 10 milliseconds. Transmitted light images were obtained every 2 min 
for the duration of 1 hour with a 20 x extra long working distance objective. Images 
were processed (AVI video) and visible cell counts were quantified with Image-J. 
Whole blood flow cytometry was performed according to Mollnes et al. 148. 
Blood was distributed in surface-heparinised FACS tubes (Corline Systems, Sweden), 
and treated with PBS, EDTA, antagonists, or corresponding control peptides. The final 
concentrations of inhibitors in blood were as follows: EDTA, 10 mM; compstatin or its 
control peptide, 60 µM; and C5aRA or its control peptide, 10 µM. The blood was split 
equally into two tubes for each condition and either MSCs or a similar volume of PBS 
was added (100 µl/ml). Different doses of MSCs were tested (0.1-1.0 x 106 cells/ml). 
Samples were incubated at 37°C, and remaining complement activity was stopped after 
40 min by the addition of EDTA. Blood sample aliquots of 100 µl were collected after 
gentle mixing, labelled for 20 min with 5 µl of antibody (anti-C3c-FITC, or CD11b-
FITC and respective isotype controls), and lysed for 5 min by adding 2 ml FACS lysing 
solution (BD). The lysed samples were centrifuged at 900g for 5 min, the supernatants 
discarded and the cells were washed once again with 3 ml of PBS; 50.000 events were 
analysed. The remaining blood volume was diluted in an equal volume of 10 mM 
PBS/EDTA and centrifuged for 5 min at 2000g to yield plasma supernatants for use in 
ELISA analysis. These supernatants were stored at -80°C until later use. 
Cell surface heparin modification: MSCs were first biotinylated by incubating 
1-2 x 106 cells/ml for 30 min in PBS containing 1 mg/ml SNL biotin (EZ-Link Sulfo-
NHS-LC-Biotin; Pierce Biotechnology, UK), followed by washing with PBS, then 
incubated for 5 min with 1 mg/ml Avidin (Pierce), washed with PBS, and then labelled 
for 30 min with 1 mg/ml macromolecular heparin-conjugate (Corline System, Sweden). 
Chandler whole blood loops: Different cell types (ECs vs. MSCs) and MSCs 
prepared in different ways (resting vs. MLR-activated cells, fresh vs. thawed cells, 
MSCs resuspended in 10% ABP or HSA, and heparin-modified vs. native MSCs) were 
exposed to blood by using the Chandler whole-blood loop system, consisting of plastic 
tubing with a heparinised inner surface (Corline Systems), as described previously 152. 
Briefly, pieces of plastic tubing containing 7 ml of human blood were prepared and 
supplemented with 100 µl PBS containing 10% ABP or HSA +/- either resting vs. 
MLR-activated MSCs, freshly harvested vs. freeze-thawed MSCs, or heparin-modified 
vs. native MSCs, and compared to resting ECs as controls. To determine the time 
course of the reaction between blood and cells, 1-ml samples from each blood tube 
were collected before cell addition and at 5, 15, 30, and 60 min after cell addition. 
Reactions were stopped by addition of 10 mM EDTA (pH 7.4). Platelet and cell counts 
were obtained for each sample by using a cell counter (Beckman Coulter, USA). 
Remaining volume was centrifuged at 3000g for 20 min at 4°C, plasma collected, and 
stored at −80°C. Formation of the blood activation markers thrombin-anti-thrombin 
complex (TAT), activated factor VII anti-thrombin complex (FVIIa-AT), FXIa-AT, 
FXIIa-AT, and complement activation makers C3a and sC5b-9, in plasma were 
measured by ELISA, according to previously described methods 153-155. 
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3.3.4 Mixed lymphocyte reactions and immunomodulation (Study I to III) 
Mixed lymphocyte reactions (MLRs) were performed as described earlier 147. 
PBMCs were prepared by centrifugation of heparinised blood on Ficoll-Isopaque 
(Lymphoprep, Norway) and cultured in RPMI 1640 medium supplemented with 
penicillin (100 U/ml), streptomycin (100 µg/ml), L-glutamine (2 mM; Invitrogen Ltd, 
UK) and 10% ABS (PAA Laboratories Ltd, UK). Responder PBMCs were stimulated 
with PHA-mitogen, or alloantigen-stimulated with a pool of allogeneic donors (n=5). 
Freeze-thawed or fresh third-party MSCs (P2-4) were irradiated (20 Gy) and added at 
1:10 ratio to PBMCs. MSC-mediated suppression of PBMC proliferation was assessed 
with 3H-thymedine incorporation (18 hours) as counts per minute (cpm), either at day 3 
to 4 (PHA-mitogen), or at day 5 to 6 (alloantigen). Following antagonists were added to 
the MLRs: linear compstatin, 20 µM; cyclic compstatin, 20 µM; and cyclic C5aR-
antagonist, 5 µM. MACS-depletion was used to remove the CD14/CD11b-high fraction 
from PBMCs (Miltenyi Biotech, Germany); additionally blocking experiments of 
complement receptor 3 (CD11b/CD18) were performed with anti-CD11b monoclonal 
(5 µg/ml; Acris Biotechnology, Germany) or respective isotype control IgG (5 µg/ml). 
Cells for gene expression (Study II): ECs, resting and MLR-activated MSCs, 
were stimulated by co-culture with activated PBMCs for 5 days in trans-well MLRs, 
and compared to unstimulated MSCs or ECs. Responder PBMCs were stimulated with 
a pool of allogeneic donors, and placed together in the top well of the culture plate; 
third-party MSCs were placed in the bottom well, at a ratio of 1:10 to PBMCs. 
IDO-expression and activity (Study III): MSCs were cultured +/- 100 U/ml 
recombinant human interferon gamma (INFg; Sigma Aldrich, UK) for 1-7 days. 
Conditioned media and cell lysates were harvested after 24 hours and 7 days of INFg. 
The indoleamine 2,3-dioxygenase (IDO) protein expression within lysates of resting or 
INFg-activated MSCs was quantified with Western blot. Proteins were solubilised in 
lysis buffer supplemented with protease inhibitors (Sigma Aldrich) 120. Lysates were 
sonicated before addition of Laemmli buffer, boiled, and to ensure equal loading, 
protein concentration was determined by BCA-protein assay (Pierce). Ten microgram 
of total protein was loaded onto a 10% SDS-PAGE, electro-blotted onto a PVDF 
membrane (Perkin-Elmer), blocked with 5% non-fat milk, and probed with primary 
IDO antibody (H-110; Santa Cruz Biotechnology, Inc., USA; 2 µg/ml) or beta-tubulin 
loading control antibody (TUB2.1; Sigma, 2.6 µg/ml), followed by washing, and 
incubation with peroxidase conjugated secondary antibody (IDO 1:2000 goat-anti-
rabbit antibody and beta-tubulin 1:3000 goat-anti-mouse; both antibodies from Dako). 
All antibodies were diluted in 2% non-fat milk for incubations. Blots were washed, and 
developed by using ECL-kit (Perkin-Elmer), and positive signal was quantified with 
densitometry after subtraction of background. The enzymatic activity of IDO within 
conditioned MSC media was determined by measuring the concentration of tryptophan 
metabolite, L-kynurenine, as outlined previously 156. Briefly 150 µl of conditioned 
media was combined with 75 µl of 30% trichloroacetic acid and centrifuged at 8000g 
for 5 min at room temperature, and 75 µl of the supernatant was combined with an 
equal volume of Ehrlich’s reagent in a 96-well plate. Absorbance was read at 492 nm 
using a micro plate reader. Concentrations of L-kynurenine in the samples were 
calculated using a standard curve of defined L-kynurenine concentrations (0-100 µM). 
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3.3.5 Expression analysis on properties of therapeutic MSCs (Study II & IV) 
EC biology QRT-PCR array and confocal microscopy: Cell lysates of ECs, 
resting and MLR-activated MSCs were harvested with RLT buffer (Qiagen, Germany), 
RNA extracted by using the Qiagen RNeasy minikit, and then stored in RNAse-free 
water at −80°C. RNA concentration and purity were estimated by reading absorbance 
at 260 / 280 nm with a spectrophotometer (Nanodrop; Thermo Fisher Scientific, USA). 
The cDNA samples used for PCR analysis were obtained with the high-capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, USA) or the RT2 PCR Array First 
Strand kit (SuperArray Bioscience, USA). QRT-PCR assays were performed using the 
human EC biology RT2 ProfilerTM PCR Array on an ABI PRISM 7900 HT Fast Block 
(data analysis available on website: http://www.superarray.com/pcr/arrayanalysis.php). 
QRT-PCRs were performed with the Applied Biosystems 7900 HT sequence detection 
system. Primers were designed for TF, collagen type-1 subunit A1 (COL1A1), and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Expression levels of GAPDH 
and Beta-Actin was used as an internal standard: Ct = Ct(Gene) − Ct(GAPDH), with Ct being 
the cycle threshold of GAPDH or the gene of interest.  Results were calibrated against a 
negative control and further analysed by the 2−∆Ct method 157. Sub-confluent cells were 
detached with trypsin, allowed to adhere to microscope slides, fixed with 70% ethanol 
containing 30% acetone, and labelled with antibodies reconstituted in PBS with 2% 
goat serum and 1% BSA. The cells were first labelled with mouse control IgG (Dako), 
or primary mouse anti-human monoclonals directed against endoglin (BD), TF 
(Calbiochem, USA), collagen type-1 or fibronectin 1 (both Sigma), and visualised with 
a secondary AlexaFluor488-conjugated goat anti-mouse antibody (Molecular Probes, 
USA). Cell-surface-immobilized heparin-conjugate was visualised with TexasRed-
conjugated avidin (1 mg/ml, Pierce), and functional antithrombin binding capacity was 
quantified with AlexaFluor488-conjugated antithrombin (1 mg/ml, Corline) 146, 158. 
Hoechst 33342 dye (Sigma) was used to detect cell nuclei. Images were acquired at 63x 
magnification with a confocal microscope (Zeiss LSM510 Meta; Carl Zeiss, Germany). 
To obtain 3D projections, several 20-µM Z-stacks were acquired and then visualized 
with IMARIS imaging software (v.6.3.1, Bitplane AG, Switzerland).  
ABO and FUT2 genotyping: Two methods for determination of ABO genotype 
were performed on DNA prepared from thawed clinical grade MSCs at the University 
Hospital Blood Centre in Lund. These included an allele-specific primer (ASP) PCR 
159, and a restriction fragment length polymorphism (RFLP) PCR 160, and FUT2 
genotyping was performed with an unpublished method developed in house. ABO 
grouping including detection of anti-A/B titers in blood was done by using automated 
serological testing based on a micro-column technique blood grouping system 
(OrthoAutoVue, Sweden) and by agglutination of erythrocytes of known blood type. 
ABO promoter methylation of clinical grade MSCs (n=4 donors) of known 
blood and secretor phenotype was analysed with MagMeDIP kit (Diagenode, Belgium) 
according to user manual, as outlined in detail in manuscript IV. Briefly, DNA from 
MSCs (n=4) was tested. Methylated DNA positive control and unmethylated DNA 
negative control were spiked into one sample in order to control for the assay.  The 
samples were analysed in a SYBR green Q-PCR assay using the following ABO 
promoter region specific primers: FW; CCCTTGACACCCTGTCTCC REV; 
AGCTTCACGGGTTCGTCTC. The primers for the methylated promoter (TSH2B) 
and the unmethylated promoter (GAPDH) controls were provided in the kit. 
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ABO transcript analysis: To study mRNA transcripts in resting or stimulated 
cells MSCs were subjected to standard differentiation or pro-inflammatory mediators, 
as outlined above. Adipogenic and osteogenic differentiation was induced 147, and 
confirmed by lipid vacuole formation and upregulation of gene aP2, and matrix 
mineralisation, respectively. To activate MSCs with cytokines, the cells were exposed 
for 5 days either to 100 U/ml IFNg (Sigma Aldrich) or to pro-inflammatory mediators 
secreted by activated PBMCs in trans-well MLRs, and harvested for PCR analysis as 
described earlier 24. Cell lysates were harvested with RLT buffer, RNA extracted, its 
concentration and purity tested, and cDNA generated, as outlined above. Expression of 
beta-actin served as standard: Ct = Ct(Gene) − Ct(Actin), with Ct being cycle threshold of 
beta-actin or gene of interest.  Results are calibrated against negative control and 
analysed by the 2−∆Ct method. 
ABO antigen expression: A highly sensitive flow cytometry assay for detection 
of low levels of ABH histo-blood group antigens, previously developed in Lund for 
quality control of blood group O converted A, B and AB red blood cells (RBCs) was 
applied 161. Its sensitivity was confirmed by detection of A-antigen on weak AX 
subgroup RBCs and detection of the minute levels of A-antigens on group B RBCs 
(data not shown in this report). Paragloboside carbohydrate antigen served as positive 
control for secondary antibody binding, blood group O MSCs served as negative 
controls for anti-A and -B detection, and MSCs labelled with secondary antibody only 
were used as baseline values. To detect antigen adsorption from culture supplements, 
cells were isolated and expanded in the presence of 10% FCS, 5% ABS, or 5% PRP, as 
described above. Additionally, adsorption of blood group A/B-antigen from clinical 
grade AB-plasma, which is used as supplement for washing, reconstitution, and clinical 
infusion of MSCs was tested. Clinical MSC preparations were thawed, briefly washed 
in 10% O plasma to remove toxic DMSO, resuspended in a small volume of PBS, and 
aliquoted in FACS tubes for incubation with different types of fresh plasmas for either 
1 or 3 hours. As positive control for A/B-antigen adsorption, MSCs were incubated 
with 100% A1B, and A2B plasma, and as a negative control with 100% O non-secretor 
plasma, and 200,000 MSCs were incubated with either 0.5ml of undiluted plasma or 
with 2ml PBS containing 10% of respective plasmas. Anti-A/B labelling and detection 
was performed on washed cells as described above. Additionally, cells were labelled 
with the PE-conjugated isotype (IgG2a), positive (CD105-PE) and negative (CD14-PE) 
detection control antibodies. All antibodies are summarised in manuscript IV. 
 
3.4 DATA ANALYSIS AND STATISTICS 
Statistical analysis was performed using ANOVA and Student’s t-test. If the data 
did not fit a normal distribution, the Mann-Whitney test or the Wilcoxon matched-pairs 
test was used (two-tailed confidence intervals, 95%; P<0.05 was considered statistically 
significant; Prism 5.0; Graphpad Software). For clinical response, differences between 
responders and non-responders were evaluated using Fisher’s exact test, or when 
appropriate, Chi2-test. 
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4 RESULTS AND DISCUSSION 
MSCs have entered an accelerated rate of clinical trial activity during the past years. 
Key challenges remain in translation to widespread clinical use, such as the incomplete 
understanding of the cells fate after systemic infusion 22, 91. This thesis aims to answer 
some of these questions, based on work presented in articles I-IV: 24, 120, 141, 142. 
 
4.1 INTERACTION OF HUMAN MSC WITH HUMAN BLOOD 
4.1.1 Expression of pro- and anticoagulant factors by MSCs 
ECs are prototypic blood compatible cells 162. It was not clear whether marrow 
MSCs have similar properties. We found, that both ECs and resting or MLR-activated 
(low passage) clinical grade MSCs expressed typical hemostatic regulators 24, including 
tissue factor pathway inhibitor, tissue- and urokinase-type plasminogen activator, and 
prostacyclin synthase. Endothelial nitric oxide synthase was more prominent in ECs, 
but its inducible form predominated in MSCs. More importantly, MSCs differed in 
expression of pro-coagulant tissue and stromal factors. While TF and collagen type 1 
were absent in ECs, they were both expressed in MSCs. Early passage MSCs (P3) 
displayed only weak TF-expression, but it increased either after prolonged culture (P6) 
or upon pro-inflammatory challenge in MLRs. Collagen was already expressed at high 
levels in low passage MSCs, and its expression further increased after extended culture, 
but was weakly down-regulated after challenge in MLRs. Thus, extended culture and 
pro-inflammatory challenge shifted MSCs neutral profile to a pro-coagulant phenotype. 
This is in agreement with Tatsumi et al. 119, who also observed up-regulation of TF 
after culture of adipose derived MSCs, initially only expressed at very low levels in 
freshly isolated cells. Similarly, Stephenne et al. 117 found strong variation in expression 
of TF and blood regulatory capacity in various cell types of mesenchymal ontogeny. 
 
4.1.2 MSCs triggering of IBMIR in the whole blood system 
We next used the Chandler whole blood loop system, in order to study the 
interaction of different types of cell products with non-anticoagulated human blood 24. 
Blood exposure of MSCs, but not ECs, lead to initiation of the coagulation cascade, as 
indicated by increased formation of thrombin and other clotting factors. The number of 
free platelets strongly decreased compared to control blood, and visible clots formed, 
with a concomitant decrease in granulocytes and monocytes, infiltrating the fibrin clot. 
Only minute amounts of complement activation products C3a and sC5b-9 could be 
detected at the used dose (15,000 cells/ml), restricted mostly to higher passage MSCs. 
Triggering of IBMIR correlated with MSCs expression of TF, could be abrogated by 
blocking agents against TF, displayed strong donor variation, and was dependent on the 
cell dose and passage number. Low passage MSCs (P1-4) elicited less IBMIR than 
MSCs harvested at higher passage (P5-8). MLR-stimulated MSCs showed stronger 
triggering of IBMIR than resting cells, going in hand with up-regulation of TF. This is 
in agreement with other investigators 117, 119, who found that the pro-coagulant activity 
of mesenchymal cells is correlated with their expression of TF, varies between cells of 
different mesenchymal ontogeny and increases after extended in vitro culture. 
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4.1.3 IBMIR response to freshly harvested or thawed MSCs 
Recent attention has been attributed to the fact that many MSC-therapeutics are 
cryobanked for immediate “off-the-shelf” availability in the clinic 26, 106, 140, suggesting 
that cryopreserved / freeze-thawed cells have impaired therapeutic properties compared 
to cultured cells, used in many pre-clinical studies to demonstrate efficacy 106, 140. We 
thus thawed low passage MSCs, washed them according to preparation for clinical use, 
and exposed them to human whole blood in the Chandler loop model. Interestingly, we 
observed strongly augmented triggering of IBMIR 141 compared to our prior experience 
with freshly harvested low passage MSCs 24. We found formation of C3a and sC5b-9, 
indicating activation of the complement cascade in response to cryopreserved cells 141. 
This was further substantiated by observations of increased complement lysis after 
exposure of cryopreserved cells to complement active normal human serum, and is in 
agreement with observations by Li et al. 121 that MSCs are injured after serum contact. 
Triggering of IBMIR, and complement activation, were reduced for culture-recovered 
MSCs handled in parallel, which also showed superior immunomodulatory activity, 
although patient analysis did not reveal improved long-term engraftment of fresh cells; 
Not to our surprise, since complement lysis was also substantial with fresh MSCs 141. 
These findings go in hand with observations by Quimby et al. 106, that systemic delivery 
of cryopreserved, but not cultured MSCs, was associated with an increased incidence of 
adverse effects in an animal model, attributed to the triggering of IBMIR. 
 
4.1.4 ABO antigen expression and IBMIR triggering by MSCs 
The ABO blood type is one of the major immunogenic barriers 128. We studied 
the possible impact of immunogenic ABO antigens on the outcome of MSC therapy, 
from ex vivo preparation, to cell infusion, and consecutive patient response evaluation. 
In agreement with earlier observations by Sundin and Schäfer 129, 130, we found that 
clinical MSCs do not inherently express or upregulate ABO blood group antigens after 
inflammatory challenge or differentiation, and did not adsorb antigens with reactivity to 
ABO antibodies upon culture with various supplements, such as FCS, ABS, or PRP 142. 
However, MSCs adsorbed small amounts of ABO-antigen form the fresh human AB 
plasma (ABP) used for washing and clinical cell infusion at our centre, which was 
dependent on the antigen concentration and adsorption time. But is the antigen amount 
sufficient to cause ABO-antibody mediated graft rejection 128, 163? It is known from 
solid organ transplantation, that predominantly adult blood type O recipients are at risk 
for early allograft rejection, due to the higher levels of anti-A/B IgG antibodies 164. 
Compared to cells washed with non-immunogenic human serum albumin (HSA), 
MSCs washed with ABP elicited stronger IBMIR responses after exposure to blood 
from healthy O-donors, containing high titers of ABO-antibodies 142. Analysis of HSCT 
recipients found only low titers of ABO antibodies at the time of MSC treatment, 
accountable to HSCT conditioning, GvHD prophylaxis, and transfusion requirements. 
Patient analysis revealed a trend for lower response in Swedish blood type O recipients, 
displaying higher amounts of circulating ABO antibodies, although overall titers were 
low in the strongly immunocompromised patients. We concluded, that native clinical 
grade MSCs are ABO-neutral, but the ABP used for washing and infusion of MSCs, 
contaminates cells with immunogenic ABO-substance, and should be substituted by 
GMP-compliant HSA, particularly when given to immunocompentent individuals. 
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4.2 INTERACTION OF MSC WITH THE COMPLEMENT SYSTEM 
4.2.1 Complement regulatory and activating properties after serum exposure 
We found a weak expression of complement regulatory molecules membrane 
cofactor protein (MCP, CD46) and decay accelerating factor (DAF, CD55), and fairly 
strong expression of protectin (CD59) on trypsin detached MSCs 120. Comparison to 
ECs harvested in a similar fashion suggested a relative lack of expression for MCP and 
DAF on MSCs, while CD59 is expressed to similarly strong levels, therefore providing 
some degree of protection from complement lysis to MSCs. Serum exposure of MSCs 
lead to complement activation and consecutive binding of complement component C3-
fragments C3b and iC3b to the surface of MSCs and the anaphylatoxin C3a could be 
detected in the supernatants, which did not occur with ECs or EDTA-inactivated serum. 
Flow cytometry suggested a fairly similar expression of all three regulators on fresh 
and thawed MSCs (DAF slightly lower on thawed cells) 141. Freshly harvested MSCs 
bound only very few immunoglobulin’s and classical or lectin complement pathway 
initiators C1q or MBL from complement active normal human AB serum (NHS) 120. 
Binding of pattern recognition molecules C1q and MBL was increased after NHS 
exposure of thawed cells, while only very small binding of Ficolins was detected 141. 
Particularly freshly thawed MSCs (P2-4), as often used in the clinic, were prone to 
complement activation and lysis, as suggested by a 80% reduction in viable counts after 
1h of NHS-exposure, while culture-derived cells were more resistant (50% lysis) 141. 
This is in agreement with other investigators who also documented presence of MCP, 
DAF, and protectin on MSCs with flow cytometry and other methods 121, 122, 165. 
Similarly to our recent findings 141, studies by Li and Soland concluded 119, 120, that 
although complement regulators are present on MSCs, the cells get overwhelmed and 
lysed by complement, and up-regulating the expression of complement regulators by 
various means was shown to antagonise complement lysis 121, 122. Adoptive transfer of 
MSCs to complement-deficient or depleted mice resulted in reduced cellular injury, as 
compared to wild type mice, indicating complement-mediated cell injury after infusion, 
which was further substantially reduced when autologous MSCs were used 121. 
 
4.2.2 Complement activating properties after lepirudin-blood exposure 
In order to study the signalling role of complement factors between complement 
activating MSCs and different types of effector cells circulating in blood, we employed 
lepirudin anti-coagulated whole blood, which does not impair complement function 148.  
To obtain a sufficient resolution with the assay, we used a higher MSC-dose in blood 
(0.1-1.0 x 106 cells/ml) compared to the blood loops and clinical dose (15,000 cells/ml), 
corresponding to a MSC:PBMC ratio of 1:10 in FACS, as typically used in MLRs 147. 
We found complement and effector cell activation after addition of MSCs to blood, 
leading to C3-fragment deposition on MSCs and anaphylatoxin generation in plasma, 
which was abrogated in the presence of Compstatin or EDTA. Compstatin and C5aR 
antagonist successfully prevented up-regulation of CD11b on PMNs and monocytes, 
which is in agreement with findings by Mollnes et al. 148. In contrast to the MSC-lysis 
studies with complement active serum, we did not observe a reduction in gated MSCs 
after exposure to complement active blood, as compared to EDTA-inactivated blood, 
interpreted as resistance to lysis, although viability of the gated cells was not tested. 
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4.2.3 Complement activation and immunomodulation by MSCs 
           We found that both the degree of complement activation elicited by MSCs, and 
the subsequent intensity of CD11b-mediated effector cell priming, were correlated with 
the capacity of these cells to suppress the proliferation of PBMCs in MLRs 120. 
Inhibition of complement with compstatin and removal of CD14/CD11b-high myeloid 
cells (monocytes) strongly impaired the immunosuppressive function of MSCs in vitro, 
going in hand with studies indicating that MSCs engage myeloid cells to elicit their 
immunosuppressive effects 29, 166-168. This suggests a role of complement activation and 
innate effector cell polarisation in MSCs immunomodulatory activity (Figure 7).  
Triggering of complement activation leads to C3 convertase-mediated cleavage 
of C3 into its active fragments C3a and C3b. The covalently bound C3b is degraded to 
iC3b by factor I. C3b and its degradation products mediate phagocytosis and may 
trigger immune responses via complement receptors, such as CD11b/CD18 on host 
cells. Accumulation of C3b leads to assembly of C5 convertase, activating C5 to C5a 
and C5b, which may lead to formation of the lytic membrane attack complex (MAC). 
Cell lysis can be prevented by the regulatory function of inhibitors such as CD59. C3a 
and C5a may induce cell activation and chemotactic responses by binding to receptors 
C3aR and C5aR on host cells or MSCs, potentially leading to a synergistic production 
of an anti-inflammatory microenvironment composed of many factors. To clarify if the 
highly suppressive MSC phenotype is actually associated with a beneficial clinical 
response in treatment of immune ailments, we quantified the average suppressive 
activity of MSCs in MLRs and correlated this value with the resulting clinical response 
to individual MSCs after treatment of acute GvHD and hemorrhagic cystitis. Highly 
suppressive MSCs did not elicit a better clinical response than average suppressors 120.  
 
 
Figure 7: Complement crosstalk with innate effectors mediates MSCs immunomodulatory effect. 
(Adapted from Moll G. and Jitschin R. et al. PLOSone - Supplement, 2011) 
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4.3 EVALUATION OF SYSTEMIC MSC DELIVERY TO PATIENTS 
4.3.1 Triggering of IBMIR by MSCs and its relevance for clinical use 
During the past decade, more than 200 infusions of MSCs were given at centres 
in Stockholm and Leiden for treatment of life-threatening complications to HSCT such 
as acute GvHD and hemorrhagic cystitis. No major adverse events were observed either 
during or after MSC infusion 18, 24, with thousands of patients in phase I studies 21, 22, 91. 
We performed a retrospective patient analysis and found a weak drop in platelet counts 
after MSC infusion (15%), but counts of leukocytes, neutrophils, lymphocytes, and 
monocytes did not show any acute changes within 24 hours. Analysis of soluble blood 
activation markers in patients’ plasma revealed a mean five-fold increase in coagulation 
marker TAT and complement activation marker C3a, whereas haemoglobin and 
hyperfibrinolysis marker D-dimer were not significantly changed after MSC infusion, 
and no significant changes in fibrinogen, albumin, or creatinine were seen, indicating 
altogether that the occurrence of thrombotic events is rather limited on a systemic level, 
at the currently applied cell dose. To date, no thrombotic events have been reported 
after systemic delivery of bone marrow MSCs, although reports of potentially lethal 
microvascular plugging and ectopic tissue formation in lungs of experimental animals 
have warned clinicians of possible risks associated with this type of delivery 87, 94, 98, 123. 
MSCs used in experimental settings are often cultured to higher passages. We found 
that higher passage MSCs (P5-8) initiated significantly more IBMIR in the loop model. 
The combination of late-passage MSCs infused at high doses may potentially 
contribute to the lethal thrombotic complications reported in animal studies. The MSCs 
used in our patients were all harvested in low passage, not exceeding passage 4, and 
very early-passage MSCs (P1-2) also appeared to yield a higher therapeutic benefit 25. 
Recent reports from Stephenne and Tatsumi 117, 119, also indicated that MSCs from 
sources other than marrow might behave very differently, particularly after expansion 
for several passages. Early passage bone marrow MSCs, with limited pro-thrombotic 
effects, may therefore generally be recommended for most clinical applications. An 
exception is the treatment for hemorrhagic cystitis or major hemorrhages, where a 
localised pro-thrombotic activity of MSCs could be desirable, to stop the bleeding at 
sites of vascular damage 19, 71. Of interest, MSCs upregulate pro-thrombotic factors 
such as TF and PF4 after encounter of activated immune cells in MLRs. Thus, 
triggering of IBMIR is potentially augmented at inflammatory sites and after 
embolisation in the microvasculature, where MSCs may encounter activated immune 
cells, such as macrophages and monocytes. Animal studies indicated 89, 90, 94, 169, that 
embolized MSCs are activated to release biologically active substances, mediating 
tissue repair by limiting stress responses and apoptosis 94, 169-171. Upon embolisation, 
MSCs were shown to modulate immuneresponses by recruiting and educating immune 
and reparative cells, which lead to a systemic shift in cytokine production 168. Most 
interestingly, chemotaxis and immunomodulatory properties of MSCs can also be 
triggered by complement activation products 28, 120, 172, which were found to be formed 
in blood after systemic infusion of MSCs. After contact with activated platelets, MSCs 
secrete fibrinolytic enzymes and exert ECM remodeling activity 62, which may 
contribute to repair of tissue damage. Thus, triggering of IBMIR after systemic infusion 
of MSCs may potentially contribute to both wound healing and immunomodulation. 
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4.3.2 Improving the therapeutic efficacy of systemically delivered MSCs 
In order to improve the efficacy of our MSCs, we conducted retrospective 
analysis of patient data, to identify any negative impactors to treatment efficacy 141, 142. 
Based on findings by Galipeau and co-workers 26, 140, that storage and reconstitution 
procedure could potentially affect the therapeutic efficacy of MSCs, we specifically 
tested this parameter within our established assays and analysed our patient cohort 141. 
Clinical response to fresh MSCs (n=9) was compared to that of thawed MSCs (n=35) in 
a comparable patient cohort matched for treatment indication and application time. 
Effects of confounding variables (MSC passage, cell dose, HLA-match, patient age), 
which could possibly influence the response to MSC therapy, were also considered in 
an attempt to separate individual effects. As the number of fresh infusions is limited, no 
multivariate analysis could be performed. No individual factor was shown to be 
significantly associated with an improved outcome, but we found a trend towards better 
response in patients receiving early passage (P1-2) and fresh MSCs. Clinical response 
appeared to be better in children than adults, but neither HLA-match, nor cell dose, 
showed any correlation to response, when corrected for the passage effect. Patients 
infused with fresh MSCs of early passage showed a 100% response rate, in comparison 
to a 50% response rate in comparable patients receiving thawed MSCs at passage 3-4. 
This difference was statistically significant, indicating potential additive positive effects 
for both of these factors, regarding the therapeutic value of the cells. Our limited 
analysis thus indicates a potentially favourable therapeutic value for freshly harvested 
cells, in addition to the previously reported advantage for very early passage cells 25, 45. 
This potentially improved outcome for giving fresh cells at very early passage is an 
important finding, which needs further investigation. We further show that an improved 
clinical response can already be achieved by using cryopreserved cells of very early 
passage (P1-2). Both, fresh and thawed MSCs had similar viability before infusion, and 
viability did not differ between responders and non-responders. We also revisited the 
retrospective evaluation for long-term engraftment in MSC-treated patients previously 
published 103, and re-evaluated the data comparing the use of freshly harvested to 
cryopreserved cells. Six of the 22 analysed infusions were with fresh MSCs, but no 
major difference in engraftment could be observed between the two groups. For both, 
freshly harvested and thawed MSCs, approximately half of the patients showed a 
positive signal for MSC donor DNA in one or more tissues, with higher positivity for 
earlier sampling 103. The only difference between fresh and thawed cells was the lungs, 
where 4/13 samples were positive for thawed MSCs, but none of the 4 samples for 
fresh cells. Analysis of MSC donor DNA in patient tissue showed limited engraftment 
for fresh and frozen MSCs alike. The absence of positive findings for fresh MSCs in 
the lungs might potentially indicate improved cell passage through the lung capillaries, 
in consistency with our in vitro findings of generally improved blood compatibility for 
freshly harvested cells. Sophisticated studies on the biodistribution of freshly harvested 
and freeze-thawed cells after systemic infusion could therefore be of interest for 
prospective studies. Also preconditioning, licensing, and activation of MSCs are 
important aspects to be considered for designing future MSC products. Importantly, 
any form of licensing protocols for cell therapeutics should be designed with 
consideration to the anticipated delivery method, e.g. if systemic delivery is used and 
cell engraftment is desired, studies of cell interaction with blood should be conducted. 
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4.4 STRATEGIES TO PREVENT OR ANTAGONISE IBMIR 
4.4.1 Means to prevent IBMIR and improve lung passage  
We explored simple variations in culture method for marrow MSCs, together 
with adjustments in preparations for clinical use, such as comparison of fresh and 
thawed cells (manuscript III) 141, and different infusion buffers (manuscript IV) 142. 
MSCs grown with different supplements such as 10% FCS, and 5% ABS or PRP, 
showed plastic adherent fibroblastic morphology, although cells grown with 5% PRP 
grew faster, appeared to be smaller, and were more abundant on a similar surface area. 
Platelet residue could easily be removed by washing the cells (Figure 8A). The smaller 
cell size of PRP-cultured cells could indeed be confirmed with CASY measurements 
(Figure 8B; peak size MSC-FCS: 22 µm, MSC-ABS: 21 µm, and MSC-PRP: 20 µm). 
Many PRP-cultures reached an average peak diameter of only 15 µm, suggesting better 
suitability of MSC-PRP for microvascular passage after systemic delivery. We thus 
compared the cells triggering of IBMIR (Figure 9C). Preliminary data suggest that both 
fresh and thawed MSCs grown with PRP (with platelet residue from medium removed) 
exhibit substantially reduced triggering of IBMIR, as indicated by lower clot formation, 
compared to cells grown with FCS or ABS. However, triggering of IBMIR could also 
be reduced for cells grown in FCS or ABS, when washing and suspending the cells in 
buffer containing 10% HSA instead of 10% ABP, or using freshly harvested cells 
obtained from culture instead of cryopreserved cells. It appeared to us, that cells grown 
in FCS are harder to detach from culture plastic (trypsin 8min) and may thus be more 
prone to activate IBMIR, while cells expanded with ABS are often very fragile and 
appeared to become senescent and disintegrate after a few passages in culture (>P5). 
 Figure 8: Triggering of IBMIR according supplement, washing buffer, and fresh vs. thawed MSCs. 
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4.4.2 Anti-thrombotic strategies to antagonise IBMIR 
Any pharmacological approach or cell surface modification to antagonise 
IBMIR has to be evaluated with consideration of bleeding risk. Thus, non-invasive cell 
surface modification with macromolecular heparin-conjugate or PEG-lipid derivatives, 
which have the capacity to reduce the triggering of IBMIR by therapeutic cells 143-146, 
may be preferred, although translation into GMP-compliant procedures is challenging. 
Alternatively, supplementation of anticoagulants to cells, such as low-dose heparin, 
hirudin, or low molecular weight dextran sulphate, is effective in reducing IBMIR 39. 
We found that MSCs can be effectively surface-modified with heparin-conjugate in a 
three-step procedure (in collaboration with Corline Systems, Sweden, Figure 9A), 
based on cell labelling with biotin and binding of macromolecular heparin-conjugate to 
therapeutic cells, by using an avidin-linker. Non-labelled cells displayed minimal 
binding of antithrombin in confocal microscopy, while labelling with heparin-conjugate 
lead to a uniform surface distribution of avidin and antithrombin binding to cells, which 
could also be confirmed with flow cytometry (Figure 9B). Blood exposure of low 
passage MSCs lead to a weak triggering of IBMIR, as demonstrated by a reduction in 
free platelets and increase in thrombin formation (Figure 9C), which could be reduced 
to background levels (dotted line) after surface modification with heparin-conjugate, or 
by supplementation of blood with soluble anticoagulants, such as low-dose heparin. 
Pre-clinical tests to translate this method into clinical use are ongoing. 
 
Figure 9: Cell surface heparin modification and soluble anticoagulants antagonize IBMIR. 
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5 CONCLUDING REMARKS 
 
5.1 SUMMARY OF MAJOR FINDINGS 
Therapeutic MSCs, as opposed to ECs, elicit the triggering of IBMIR after exposure to 
human blood in vitro and after systemic MSC infusion into patients. 
 
MSCs express similar hemostatic regulators as ECs, but display higher amounts of pro-
thrombotic tissue / stromal factors on their surface, which trigger activation of IBMIR. 
 
Triggering of the IBMIR in vitro is characterised by activation of the complement and 
coagulation cascades, platelet activation, clot formation, and effector cell infiltration. 
 
In patients, the occurrence of thrombotic reactions to MSCs is minimal, but IBMIR 
may promote graft embolization and consecutive damage in the microvasculature. 
 
Triggering of IBMIR by therapeutic MSCs: 
 
1) Shows considerable cell donor variation, which appears to be the strongest 
single confounding factor when comparing different types of MSC isolates. 
2) Generally increases after prolonged ex vivo expansion. Early-passage MSCs 
(P1-4) elicit a weaker trigger of IBMIR than higher passage cells (P5-8). 
3) Is augmented for cryopreserved / freeze-thawed cells, as opposed to fresh cells, 
and thawed cells also display impaired immunomodulatory activity.  
4) Is weakly augmented for cells resuspended in fresh human donor AB plasma, as 
opposed to cells resuspended in GMP-compliant human serum albumin. 
5) Is dose dependent; regular doses of low passage cells are safe in patients, but 
higher doses and particularly higher passage cells should be handled with care. 
 
In conclusion, in vitro exposure of MSCs to human blood elicits triggering of IBMIR, 
which is affected by their degree of expansion, and is stronger for freeze-thawed cells 
resuspended in AB plasma (clinical use), potentially compromising cell graft function.  
 
This seems to be paired by clinical observations, that particularly early passage cells 
show the most beneficial clinical effect, with further indications for a better outcome 
when using fresh cells and eliminating the AB plasma in washing and infusion buffers. 
 
Apart from compromising cell graft survival and function, activation of IBMIR may 
also lead to formation of blood activation products, such as anaphylatoxins, which were 
shown to trigger the chemotactic and immunomodulatory properties of these cells. 
 
Triggering of IBMIR, tissue injury, and acute inflammation may therefore be crucial 
for promoting the context dependent repair functions of surviving therapeutic cells, 
once the critical phase is passed and MSCs have adapted to their new environment. 
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5.2 EPILOGUE: THE PERFECT THERAPEUTIC MESENCHYMAL 
MSCs are tested for a large variety of clinical treatment indications. A frequently asked 
question would be: What kind of general properties should our therapeutic MSCs have? 
Is the triggering of IBMIR generally a good or a bad thing for MSC therapy? 
 
Two ideas seem to predominate: 
 
1) The transplanted MSCs engraft and form tissue, and 2) MSCs are “magic bullets”, 
eliciting a certain clinical response, not necessarily requiring long-term engraftment 32. 
 
Engraftment of expanded cells may not always be desirable simply for safety reasons. 
The preferred level and time span of therapeutic cells persistence in vivo may in fact be 
depended on the intended long-term function in specific patient groups.  
 
Long-term engraftment and tissue formation of culture-expanded infused MSCs is low, 
presumably due to the poor homing efficacy to suitable target and engraftment sites, 
with donor chimerism rates of 1-5% in experimental animal models 32. 
 
When talking about tissue replacement, cell engraftment is indeed essential. However, 
tissue repair, regeneration, and modulation of immune responses may also occur 
without therapeutic cell engraftment. Would it be augmented if MSCs survive longer?  
 
If therapeutic cell function would be dependent on a transient level of engraftment, the 
first issue to consider would be the general mode of cell delivery. The cells could either 
be injected locally or delivery systemically, e.g. by intravenous or intraarterial infusion. 
 
If MSCs are applied systemically, and medium to long-term engraftment is desired, 
they should fundamentally be compatible with human blood, and furthermore they 
should not be recognised as “foreign cells” by the recipient immune system. 
 
Accordingly, a better therapeutic mesenchymal would display the following properties: 
 
It is shortly expanded in culture (early passage) with minimum epigenetic alterations. 
It does not trigger the IBMIR (e.g. does not activate complement and clotting system). 
It does not express or display any incompatibility / foreign epitopes on its cell surface. 
It does not bind any type of natural antibodies and does not trigger effector cell lysis. 
It efficiently homes to the desired target site / tissues in vivo (e.g. tissue damage site). 
It transiently engrafts at the target sites and forms / regenerates the appropriate tissue. 
It elicits strong and long-lasting modulation of immune effector cell function in vivo. 
 
Can this hypothetical scenario ever be achieved? I think that detailed studies, and 
consequent stepwise improvements in cell production and their mode of application, 
combined with an improved patient supportive care, will eventually achieve this goal. 
 
I would like to close here with the words of Bakunin: “By striving to do the impossible, 
man has always achieved what is possible.” 
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